Search
Ponazuril
go.drugbank.com/drugs/DB11452ExperimentalVet approvedPonazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Trilostane
go.drugbank.com/drugs/DB01108ApprovedVet approvedWithdrawnTrilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Categories: Corticosteroids for Systemic UseLP-2307
go.drugbank.com/drugs/DB17470ExperimentalLP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Talopram
go.drugbank.com/drugs/DB09190ExperimentalTalopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalAlthough it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials. … It has a 55 percent amino acid residue identity to Fibroblast Growth Factor 1 and has potent heparin-binding activity.
Sulbutiamine
go.drugbank.com/drugs/DB13416InvestigationalSulbutiamine is a synthetic derivative of thiamine (vitamin B1) under the market name Arcalion that is composed of two modified thiamine molecules to form a dimer. … Although its clinical efficacy is not yet defined, sulbutiamine is used to treat asthenia.
TT 173
go.drugbank.com/drugs/DB17717InvestigationalTT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental
Amodiaquine
go.drugbank.com/drugs/DB00613ApprovedInvestigationalA 4-aminoquinoquinoline compound with anti-inflammatory properties.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThese cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies. … These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalIt is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.